From the resultant dataset, we selected those with stock prices under $10 and ranked them ... MannKind Corporation (NASDAQ:MNKD) develops inhaled therapies for diabetes, with Afrezza as its ...

MNKD Price Action: According to Benzinga Pro ... CNBC's Jim Cramer mentioned the stock on the “Mad Money Lightning Round” Friday. MannKind has been “hanging out there forever, and it's ...

Shares of Mannkind (MNKD) rose 7% in post-market trading Wednesday after the company issued its Q4 earnings report and a business update. Read more here.

MannKind (MNKD) delivered earnings and revenue surprises of 0% and 1.48%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Sarepta Therapeutics (SRPT – Research Report), ...

Wells Fargo analyst Tiago Fauth maintained a Buy rating on MannKind (MNKD – Research Report) yesterday and set a price target of $9.00. The ...

Investors eyeing a purchase of MannKind Corp (Symbol: MNKD) stock, but tentative about paying the going market price of $4.96/share, might benefit from considering selling puts among the ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Participation from Market Makers and ECNs is strictly voluntary and as a result, these sessions may offer less liquidity and inferior prices. Stock prices may also move more quickly in this ...